ES2665958T3 - Anticuerpos monoclonales contra las variantes de hemoglobina C, S, E y D - Google Patents
Anticuerpos monoclonales contra las variantes de hemoglobina C, S, E y D Download PDFInfo
- Publication number
- ES2665958T3 ES2665958T3 ES16155015.7T ES16155015T ES2665958T3 ES 2665958 T3 ES2665958 T3 ES 2665958T3 ES 16155015 T ES16155015 T ES 16155015T ES 2665958 T3 ES2665958 T3 ES 2665958T3
- Authority
- ES
- Spain
- Prior art keywords
- hemoglobin
- antibody
- variants
- glycated
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010054147 Hemoglobins Proteins 0.000 title claims abstract description 68
- 102000001554 Hemoglobins Human genes 0.000 title claims abstract description 68
- 238000001514 detection method Methods 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 3
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 claims 1
- 241000220317 Rosa Species 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- 150000001413 amino acids Chemical group 0.000 description 20
- 239000000427 antigen Substances 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 16
- 238000009739 binding Methods 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 14
- 238000003556 assay Methods 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 8
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 208000002903 Thalassemia Diseases 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 239000000539 dimer Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000007837 multiplex assay Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 108091005995 glycated hemoglobin Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000011324 bead Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 208000037551 Hemoglobin D disease Diseases 0.000 description 2
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 2
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000012867 alanine scanning Methods 0.000 description 2
- 208000005980 beta thalassemia Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 108010013766 hemoglobin A(0) Proteins 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010044495 Fetal Hemoglobin Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 108010027616 Hemoglobin A2 Proteins 0.000 description 1
- 108091005880 Hemoglobin F Proteins 0.000 description 1
- -1 IgM Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010016797 Sickle Hemoglobin Proteins 0.000 description 1
- 208000000859 Sickle cell trait Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000035203 thalassemia minor Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/723—Glycosylated haemoglobin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26248809P | 2009-11-18 | 2009-11-18 | |
| US262488P | 2009-11-18 | ||
| US12/941,738 US8603828B2 (en) | 2009-11-18 | 2010-11-08 | Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms |
| US941738 | 2010-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2665958T3 true ES2665958T3 (es) | 2018-04-30 |
Family
ID=44011571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16155015.7T Active ES2665958T3 (es) | 2009-11-18 | 2010-11-09 | Anticuerpos monoclonales contra las variantes de hemoglobina C, S, E y D |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US8603828B2 (enExample) |
| EP (3) | EP3301452B1 (enExample) |
| JP (2) | JP6139886B2 (enExample) |
| AU (3) | AU2010322233B2 (enExample) |
| CA (1) | CA2781255C (enExample) |
| ES (1) | ES2665958T3 (enExample) |
| PT (1) | PT3043182T (enExample) |
| WO (1) | WO2011062803A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8603828B2 (en) | 2009-11-18 | 2013-12-10 | Bio-Rad Laboratories, Inc. | Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms |
| US11435358B2 (en) | 2011-06-23 | 2022-09-06 | Board Of Regents, The University Of Texas System | Single molecule peptide sequencing |
| WO2015099123A1 (ja) * | 2013-12-26 | 2015-07-02 | 京セラ株式会社 | センサ |
| WO2015143394A1 (en) * | 2014-03-20 | 2015-09-24 | Bio-Rad Laboratories, Inc. | Glycated protein assay |
| US10288628B2 (en) | 2014-04-11 | 2019-05-14 | Siemens Healthcare Diagnostics Inc. | Spectroscopic methods for the detection of glycated hemoglobin |
| US20160116489A1 (en) * | 2014-10-23 | 2016-04-28 | Biomedomics, Inc. | Lateral flow immunoassay method of simultaneously detecting hemoglobin s, hemoglobin c, and hemoglobin a in newborns, infants, children, and adults |
| US10545158B2 (en) * | 2014-12-29 | 2020-01-28 | North Carolina State University | Multiplexed diagnostic to recognize concentrations of related proteins and peptides |
| CN114923837B (zh) | 2015-02-09 | 2025-09-19 | 弹弓生物科学公司 | 具有可调光学性质的水凝胶颗粒以及使用其的方法 |
| JP6492856B2 (ja) * | 2015-03-25 | 2019-04-03 | 東ソー株式会社 | 安定型糖化ヘモグロビンＡ１ｃの定量方法 |
| EP3365012A1 (en) * | 2015-10-21 | 2018-08-29 | Qoolabs, Inc. | Camelid hemoglobin antibodies and methods of use |
| US10670615B2 (en) | 2015-12-04 | 2020-06-02 | Polymer Technology Systems, Inc. | Systems and methods for interference correction from hemoglobin variants |
| US11091004B2 (en) | 2016-02-17 | 2021-08-17 | Denso Corporation | Air conditioning unit for vehicle |
| US12345718B2 (en) * | 2016-11-04 | 2025-07-01 | Université Paris Est Créteil Val De Marne | Method for determining the haemoglobin content of an erythroid cell |
| US10317413B2 (en) | 2016-11-14 | 2019-06-11 | The Board Of Regents Of The University Of Texas System | Method and kit for detection of anti-zika virus antibodies |
| US11535681B2 (en) * | 2017-12-15 | 2022-12-27 | Bluebird Bio, Inc. | Sickled beta globin antibodies |
| EP3821010A4 (en) | 2018-07-12 | 2022-04-20 | Board of Regents, The University of Texas System | Molecular neighborhood detection by oligonucleotides |
| KR20210068048A (ko) * | 2018-09-28 | 2021-06-08 | 세키스이 메디칼 가부시키가이샤 | 당화 헤모글로빈(％)의 측정 방법 |
| JP2022504225A (ja) | 2018-10-05 | 2022-01-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 固相でのｎ末端ペプチド捕捉および解放の方法 |
| EP3942059A4 (en) * | 2019-03-04 | 2022-04-20 | Siemens Healthcare Diagnostics, Inc. | STABILIZATION OF THE SURFACE POLYSACCHARID AREA OF A DRIED REAGENT |
| US20200284807A1 (en) * | 2019-03-05 | 2020-09-10 | Victor Manneh | Saturation binding ratiometric assay |
| CA3165821A1 (en) | 2020-01-24 | 2021-07-29 | Jeffrey Kim | Compositions and methods for cell-like calibration particles |
| EP4147049A1 (en) | 2020-05-04 | 2023-03-15 | Slingshot Biosciences, Inc. | Compositions and methods for passive optical barcoding for multiplexed assays |
| KR20240116721A (ko) | 2021-10-29 | 2024-07-30 | 슬링샷 바이오사이언시즈 인코포레이티드 | 피더 세포 및 합성 항원 제시 세포로서의 하이드로겔 입자 |
| JPWO2023195348A1 (enExample) * | 2022-04-04 | 2023-10-12 | ||
| WO2023196898A1 (en) * | 2022-04-07 | 2023-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Beta globin mimetic peptides and their use |
| AU2023265684A1 (en) | 2022-05-05 | 2024-11-21 | Slingshot Biosciences, Inc. | Engineered particles as red blood cell mimics and compositions containing same for hematology |
| CN119546284A (zh) | 2022-06-02 | 2025-02-28 | 弹弓生物科学公司 | 凋亡细胞模拟物 |
| EP4608872A2 (en) | 2022-10-26 | 2025-09-03 | Slingshot Biosciences, Inc. | Size-tunable synthetic particles with tunable optical properties and methods for using the same for immune cell activation |
| US12461007B2 (en) | 2023-08-29 | 2025-11-04 | Slingshot Biosciences, Inc. | CD34 stem cell mimics |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2632478A1 (de) | 1975-07-23 | 1977-02-24 | Coulter Electronics | Verfahren zur erfassung und trennung von antigenen und antikoerperchen im blut und in anderen proben |
| US4752583A (en) * | 1984-11-29 | 1988-06-21 | The United States Of America As Represented By The United States Department Of Energy | Monoclonal antibodies to human hemoglobin S and cell lines for the production thereof |
| US5428754A (en) | 1988-03-23 | 1995-06-27 | 3Dlabs Ltd | Computer system with clock shared between processors executing separate instruction streams |
| US5922854A (en) * | 1991-06-14 | 1999-07-13 | Kumar; Ramesh | Purifying Human Hemogloblin from transgenic pig red cells and plasmids containing pig globin nucleic acids |
| WO1993018407A1 (en) * | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Determination of glycated hemoglobin by fluorescence quenching |
| US6043043A (en) * | 1993-04-02 | 2000-03-28 | Bayer Corporation | Method for the determination of hemoglobin adducts |
| US6951716B2 (en) * | 1995-03-13 | 2005-10-04 | Mark Hechinger | Anti-platelet immunoglobulin bead positive control |
| US6933106B2 (en) * | 1995-03-13 | 2005-08-23 | Mark Hechinger | Platelet immunoglobulin bead suspension and flow cytometry |
| EP1015028A2 (en) * | 1997-09-19 | 2000-07-05 | Serex, Inc. | Methods to improve immunogenicity of antigens and specificity of antibodies |
| US7271009B1 (en) * | 1997-11-18 | 2007-09-18 | Bio-Rad Laboratories, Inc. | Multi-analyte diagnostic test for thyroid disorders |
| EP0965044B1 (en) * | 1997-11-18 | 2003-03-19 | Bio-Rad Laboratories, Inc. | Multiplex flow immunoassays with magnetic particles as solid phase |
| WO1999064867A1 (en) * | 1997-12-04 | 1999-12-16 | Amersham Pharmacia Biotech Uk Limited | Multiple assay method |
| US20020115116A1 (en) * | 2001-02-22 | 2002-08-22 | Yong Song | Multiplex protein interaction determinations using glutathione-GST binding |
| DE60234933D1 (de) * | 2001-04-26 | 2010-02-11 | Dako Denmark As | Pan-spezifischer monoklonaler antikörper der gegen glycosiliertes hämoglobin gerichtet ist |
| AU2003223520A1 (en) * | 2002-04-12 | 2003-10-27 | Mitokor | Targets for therapeutic intervention identified in the mitochondrial proteome |
| US7326573B2 (en) * | 2003-01-10 | 2008-02-05 | Beckman Coulter, Inc. | Assay procedures and apparatus |
| US20040229284A1 (en) * | 2003-02-19 | 2004-11-18 | The Regents Of The University Of California | Multiplex analysis of proteins |
| US20040214243A1 (en) * | 2003-04-25 | 2004-10-28 | Beckman Coulter, Inc. | Differential determination of hemoglobins |
| US7150995B2 (en) * | 2004-01-16 | 2006-12-19 | Metrika, Inc. | Methods and systems for point of care bodily fluid analysis |
| WO2005116607A1 (en) * | 2004-05-27 | 2005-12-08 | Monash University | A method for the rapid analysis of polypeptides |
| JP2006052480A (ja) | 2004-08-10 | 2006-02-23 | Nisshinbo Ind Inc | セルロース系繊維含有布帛の加工方法及びセルロース系繊維含有布帛 |
| GB0502068D0 (en) * | 2005-02-01 | 2005-03-09 | King S College London | Screening method |
| EP1889906A4 (en) | 2005-06-03 | 2009-06-03 | Nipro Corp | VECTOR WITH HIGH COPY AND HIGH EXPRESSION AND WITH METHIONINAMINOPEPTIDASE GENE INCLUDED |
| US7521244B2 (en) * | 2006-10-26 | 2009-04-21 | Bionostics, Inc. | Standard reference solutions |
| WO2009067421A1 (en) * | 2007-11-20 | 2009-05-28 | Siemens Heathcare Diagnostics Inc. | Methods for the detection of glycated hemoglobin |
| US8260556B2 (en) | 2008-08-21 | 2012-09-04 | Bio-Rad Laboratories, Inc. | Calibration surface method for determination on of analyte ratios |
| CA2765457A1 (en) * | 2009-07-07 | 2011-01-13 | Uvic Industry Partnerships Inc. | Methods for early detection of blood disorders |
| US8603828B2 (en) * | 2009-11-18 | 2013-12-10 | Bio-Rad Laboratories, Inc. | Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms |
-
2010
- 2010-11-08 US US12/941,738 patent/US8603828B2/en active Active
- 2010-11-09 WO PCT/US2010/055952 patent/WO2011062803A2/en not_active Ceased
- 2010-11-09 EP EP17201427.6A patent/EP3301452B1/en active Active
- 2010-11-09 EP EP16155015.7A patent/EP3043182B1/en active Active
- 2010-11-09 PT PT161550157T patent/PT3043182T/pt unknown
- 2010-11-09 EP EP10832004.5A patent/EP2502080B1/en active Active
- 2010-11-09 ES ES16155015.7T patent/ES2665958T3/es active Active
- 2010-11-09 AU AU2010322233A patent/AU2010322233B2/en not_active Ceased
- 2010-11-09 CA CA2781255A patent/CA2781255C/en active Active
- 2010-11-09 JP JP2012539940A patent/JP6139886B2/ja active Active
-
2013
- 2013-11-15 US US14/081,799 patent/US9213034B2/en active Active
-
2015
- 2015-10-23 JP JP2015209371A patent/JP2016028254A/ja active Pending
- 2015-11-20 US US14/947,939 patent/US9605060B2/en active Active
-
2017
- 2017-02-03 AU AU2017200733A patent/AU2017200733B2/en not_active Ceased
- 2017-02-24 US US15/441,455 patent/US10088488B2/en active Active
-
2018
- 2018-09-27 US US16/145,021 patent/US11262366B2/en active Active
-
2019
- 2019-01-07 AU AU2019200070A patent/AU2019200070B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013511717A (ja) | 2013-04-04 |
| EP3043182A1 (en) | 2016-07-13 |
| EP3043182B1 (en) | 2018-01-17 |
| US10088488B2 (en) | 2018-10-02 |
| EP3301452B1 (en) | 2020-01-08 |
| CA2781255A1 (en) | 2011-05-26 |
| US8603828B2 (en) | 2013-12-10 |
| EP3301452A1 (en) | 2018-04-04 |
| AU2010322233A1 (en) | 2012-06-21 |
| AU2019200070B2 (en) | 2020-07-16 |
| US20110117670A1 (en) | 2011-05-19 |
| AU2019200070A1 (en) | 2019-01-31 |
| JP6139886B2 (ja) | 2017-05-31 |
| AU2017200733B2 (en) | 2018-10-11 |
| US9213034B2 (en) | 2015-12-15 |
| CA2781255C (en) | 2017-08-01 |
| AU2017200733A1 (en) | 2017-02-23 |
| EP2502080A2 (en) | 2012-09-26 |
| EP2502080B1 (en) | 2016-04-13 |
| EP2502080A4 (en) | 2013-03-27 |
| US9605060B2 (en) | 2017-03-28 |
| US20170176462A1 (en) | 2017-06-22 |
| US20160068594A1 (en) | 2016-03-10 |
| US20140073532A1 (en) | 2014-03-13 |
| WO2011062803A2 (en) | 2011-05-26 |
| PT3043182T (pt) | 2018-04-23 |
| WO2011062803A3 (en) | 2011-07-28 |
| US11262366B2 (en) | 2022-03-01 |
| AU2010322233B2 (en) | 2016-11-03 |
| JP2016028254A (ja) | 2016-02-25 |
| US20190018023A1 (en) | 2019-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2665958T3 (es) | Anticuerpos monoclonales contra las variantes de hemoglobina C, S, E y D | |
| DK2379601T3 (en) | Anti-idiotypic antibody to an antibody to amyloid BETA PEPTIDE | |
| JPWO2020067396A1 (ja) | 糖化ヘモグロビン（％）の測定方法 | |
| WO2002004484A2 (en) | Hcv mosaic antigen composition | |
| JP2011505390A (ja) | リウマチ性関節炎自己抗体との免疫反応性合成ペプチド | |
| EP1414860B1 (en) | Anti-glycated hemoglobin pan-specific monoclonal antibody | |
| JP7291659B2 (ja) | アデノウイルスの免疫測定方法及び免疫測定器具 | |
| JP7454546B2 (ja) | Ｅ型肝炎ウイルスのＯＲＦ２ｉタンパク質に対して特異性を有する抗体及びその診断目的のための使用 | |
| KR102397684B1 (ko) | 항체의 항원 결합 부위에 결합하는 펩티드 및 이를 이용한 분석 방법 | |
| KR102004693B1 (ko) | 지카 바이러스의 외막 단백질에 특이적으로 결합하는 펩티드 및 이의 용도 | |
| WO2023195347A1 (ja) | 抗ヒトヘモグロビンβ鎖モノクローナル抗体又はその抗原結合性断片、ヒトヘモグロビン及び／又は糖化ヒトヘモグロビンを検出する方法、ヒトヘモグロビン及び／又は糖化ヒトヘモグロビンの検出キット、並びに、ペプチド | |
| JP2007254428A (ja) | 天然で未変性のｃｄｔに対する抗体、抗体の製造方法、ハイブリドーマ、及び免疫測定方法 | |
| JP2002000268A (ja) | モノクローナル抗体 |